First Oral Treatment for Relapsed, Refractory Acute Myeloid Leukemia Wins FDA Approval
August 1st 2017Officials with the FDA have approved enasidenib (Idhifa, Celgene Corporation) to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation, isocitrate dehydrogenase-2 (IDH2), according to a FDA press release.
Read More